N/A N=94 Randomized Quadruple-blind Treatment

Memantine Treatment in Fragile X-Associated Tremor/Ataxia Syndrome

Fragile X-Associated Tremor/Ataxia Syndrome · Fragile X Premutation Carriers

Bottom Line

View on ClinicalTrials.gov: NCT00584948 ↗

Enrolled (actual)

Serious AEs

5.3%

Results posted

Apr 2017

Primary outcome: Primary: Change From Baseline in Executive Functioning as Measured by the Behavioral Dyscontrol Scale II (BDS-II) — 17.44; 16.12; 15.66; 15.72 units on a scale

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Memantine (Drug); Placebo (Drug)
Age: Adult, Older Adult · 30+ yrs
Sex: All
Sponsor: University of California, Davis
Primary completion: Sep 2012

Outcome Measures

Outcome	Result	p-value
PRIMARY Change From Baseline in Executive Functioning as Measured by the Behavioral Dyscontrol Scale II (BDS-II)	17.44; 16.12; 15.66; 15.72	—
PRIMARY Change From Baseline in Intention Tremor as Measured by the CATSYS Tremor Scale	1.31; 1.05; 1.77; 1.89	—

Summary

The purpose of this study is to determine if memantine is effective in treating symptoms of Fragile X-associated Tremor Ataxia Syndrome.

Eligibility Criteria

Inclusion Criteria

Fragile X premutation carrier (CGG repeat 55-200)with neurological symptoms; Clinical FXTAS Stage 1-5

Exclusion Criteria

Previous reaction to memantine

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00584948). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.